Search

Date 2015 Author/Creator McIntosh, Stuart

1. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. Issue 2 (December 2015)

Authors:
Rizvi, Naiyer; Barlesi, Fabrice; Brahmer, Julie; Felip, Enriqueta; Forde, Patrick; Garassino, Marina; Goldberg, Sarah; Vansteenkiste, Johan; Jarkowski, Anthony; McIntosh, Stuart; Zhao, Luping; Antonia, Scott
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. (4th November 2015)

Authors:
Rizvi, Naiyer; Barlesi, Fabrice; Brahmer, Julie; Felip, Enriqueta; Forde, Patrick; Garassino, Marina; Goldberg, Sarah; Vansteenkiste, Johan; Jarkowski, Anthony; McIntosh, Stuart; Zhao, Luping; Antonia, Scott
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search